As we near the release of GastroPlus™ 9.6, Simulations Plus will host a webinar on Tuesday, April 24th to introduce the new capabilities.
Discovery PBPK: How to enhance the expected accuracy of bioavailability predictions for NCEs that are not primarily metabolized.
Join us for hands-on PBPK modeling, Quantitative Systems Pharmacology (QSP), and population PK/PD data analyses training near you. Space is limited, so register soon!
Our experts are able to help you from the point at which you begin sketching chemical structures, all the way through regulatory filings!
DILIsym® is Quantitative systems toxicology (QST) software for modeling drug-induced liver injury (DILI). Learn about the latest updates in version 7A.
To improve the productivity of science-based research & development enterprises by delivering innovative modeling and simulation software and insightful consulting services.
Ensuring the safety of drug therapies by leveraging our expertise in the areas of drug-induced liver injury, metabolic diseases, and modeling and simulation.
Providing strategic pharmacology and pharmacometric consulting services, PK/PD model development with NONMEM, clinical trial simulations, exposure-response evaluations, dose justification strategies and related data management services.
While our focus for the solutions we provide was initially targeted for pharmaceutical research & development, we have earned a sound reputation in other markets as we develop stronger relationships with regulatory agencies like the U.S. FDA, U.S. EPA, EMA, PMDA, ECHA, and more.
Stay up-to-date with our upcoming conference attendance & presentations, application webinars, and training workshop courses.
Find out how your peers are applying our technology by reviewing journal articles describing various user case studies.